{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:46:54Z","timestamp":1791866814181,"version":"4.3.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01430-4","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:20:34Z","timestamp":1789140034000},"page":"2865-2894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Narrative Review of Two-Drug Regimens in Modern HIV Care: Driving Innovation, Flexibility, and Quality of Life"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-6358","authenticated-orcid":false,"given":"Lucia","family":"Taramasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Muccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rossotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"5","key":"1430_CR1","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, Crane H, d\u2019Arminio Monforte A, Egger M, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295-307. https:\/\/doi.org\/10.1016\/S2352-3018(23)00028-0.","journal-title":"Lancet HIV"},{"key":"1430_CR2","unstructured":"Department of Health and Humen Services (DHHS). A timeline of HIV and AIDS. https:\/\/www.hiv.gov\/hiv-basics\/overview\/history\/hiv-and-aids-timeline."},{"key":"1430_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03546-y","author":"J Tuzil","year":"2026","unstructured":"Tuzil J, Christoph MJ, Chen M, Lach K, Haloski K, Park S, et al. Systematic literature review and meta-analysis of INSTI-based antiretroviral therapy single- versus multiple-tablet regimens for the treatment of HIV. Adv Ther. 2026. https:\/\/doi.org\/10.1007\/s12325-026-03546-y.","journal-title":"Adv Ther"},{"issue":"6","key":"1430_CR4","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1007\/s10461-020-03125-4","volume":"25","author":"T Sangaramoorthy","year":"2021","unstructured":"Sangaramoorthy T, Haddix M, Agopian A, Yellin H, Mouhanna F, Abdi H, et al. Measuring unmet needs among persons living with HIVat different stages of the care continuum. AIDS Behav. 2021;25(6):1954\u201367. https:\/\/doi.org\/10.1007\/s10461-020-03125-4.","journal-title":"AIDS Behav"},{"issue":"2","key":"1430_CR5","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1016\/S2352-3018(19)30343-1","volume":"7","author":"GZ Andersson","year":"2020","unstructured":"Andersson GZ, Reinius M, Eriksson LE, Svedhem V, Esfahani FM, Deuba K, et al. Stigma reduction interventions in people living with HIV to improve health-related quality of life. Lancet HIV. 2020;7(2):e129\u201340. https:\/\/doi.org\/10.1016\/S2352-3018(19)30343-1.","journal-title":"Lancet HIV"},{"key":"1430_CR6","unstructured":"Food and Drug Administration. FDA approves cabenuva and vocabria for the treatment of HIV-1 infection. https:\/\/www.fda.gov\/drugs\/human-immunodeficiency-virus-hiv\/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection."},{"issue":"4","key":"1430_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","volume":"85","author":"G Rizzardini","year":"2020","unstructured":"Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, G\u00f3rgolas Hern\u00e1ndez-Mora M, et al. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020;85(4):498\u2013506. https:\/\/doi.org\/10.1097\/QAI.0000000000002466.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"1430_CR8","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","volume":"24","author":"M Murray","year":"2020","unstructured":"Murray M, Antela A, Mills A, Huang J, J\u00e4ger H, Bernal E, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS Behav. 2020;24(12):3533\u201344. https:\/\/doi.org\/10.1007\/s10461-020-02929-8.","journal-title":"AIDS Behav"},{"issue":"9","key":"1430_CR9","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"MN Ramgopal","year":"2023","unstructured":"Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566\u201377. https:\/\/doi.org\/10.1016\/S2352-3018(23)00136-4.","journal-title":"Lancet HIV"},{"issue":"1","key":"1430_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10461-024-04490-0","volume":"29","author":"C Mussini","year":"2025","unstructured":"Mussini C, Cazanave C, Adachi E, Eu B, Alonso MM, Crofoot G, et al. Improvements in patient-reported outcomes after 12 months of maintenance therapy with cabotegravir + rilpivirine long-acting compared with bictegravir\/emtricitabine\/tenofovir alafenamide in the phase 3b SOLAR study. AIDS Behav. 2025;29(1):64\u201376. https:\/\/doi.org\/10.1007\/s10461-024-04490-0.","journal-title":"AIDS Behav"},{"key":"1430_CR11","unstructured":"Rolle CP, Hove K, Cahn P, Szabo J, Perez CM, Urbieta JB, et al. Early switch to CAB+RPV LA in treatment-naive adults with HIV-1: month 11 outcomes from VOLITION [oral presentatin]. Abstract number 525. 2026 Feb 22 [cited 2026 Mar 12]; Denver. https:\/\/www.croiconference.org\/abstract\/2291-2026\/."},{"issue":"10167","key":"1430_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"P Cahn","year":"2019","unstructured":"Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(18)32462-0.","journal-title":"Lancet"},{"issue":"1","key":"1430_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/cid\/ciaf415","volume":"82","author":"MI Figueroa","year":"2026","unstructured":"Figueroa MI, Brites C, Cecchini D, Ramalho A, Francos JL, Lacerda M, et al. Efficacy and safety of dual therapy with dolutegravir\/lamivudine in treatment-naive persons with CD4 counts <200\/mm3: 48-week results of the DOLCE study. Clin Infect Dis. 2026;82(1):122\u201331. https:\/\/doi.org\/10.1093\/cid\/ciaf415.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1430_CR14","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, et al. Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide\u2013based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920\u20139. https:\/\/doi.org\/10.1093\/cid\/ciz1243.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1430_CR15","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","volume":"6","author":"M Aboud","year":"2019","unstructured":"Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, et al. Efficacy and safety of dolutegravir\u2013rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019;6(9):e576\u201387. https:\/\/doi.org\/10.1016\/S2352-3018(19)30149-3.","journal-title":"Lancet HIV"},{"issue":"4","key":"1430_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac130.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1430_CR17","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1016\/S2352-3018(25)00105-5","volume":"12","author":"P Ryan","year":"2025","unstructured":"Ryan P, Blanco JL, Masia M, Garcia-Fraile L, Crusells MJ, Domingo P, et al. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV. 2025;12(7):e473\u201384. https:\/\/doi.org\/10.1016\/S2352-3018(25)00105-5.","journal-title":"Lancet HIV"},{"issue":"8","key":"1430_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/hiv.13647","volume":"25","author":"M John","year":"2024","unstructured":"John M, Williams L, Nolan G, Bonnett M, Castley A, Nolan D. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS). HIV Med. 2024;25(8):935\u201345. https:\/\/doi.org\/10.1111\/hiv.13647.","journal-title":"HIV Med"},{"issue":"24","key":"1430_CR19","doi-asserted-by":"publisher","first-page":"00289","DOI":"10.1016\/S1473-3099(24)00289-5","volume":"S1473\u20133099","author":"C Kityo","year":"2024","unstructured":"Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024;S1473\u20133099(24):00289\u201395. https:\/\/doi.org\/10.1016\/S1473-3099(24)00289-5.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1430_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jama.2024.2985","volume":"331","author":"PE Sax","year":"2024","unstructured":"Sax PE, Thompson MA, Saag MS, IAS-USA Treatment Guidelines Panel. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel. JAMA. 2024;331(12):1060\u20131. https:\/\/doi.org\/10.1001\/jama.2024.2985.","journal-title":"JAMA"},{"issue":"7","key":"1430_CR21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/hiv.70025","volume":"26","author":"B Barda","year":"2025","unstructured":"Barda B, Barilaro G, Bellini P, Turicchi G, Bernasconi E, Bongiovanni M. Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: a systematic review and meta-analysis. HIV Med. 2025;26(7):993\u20131003. https:\/\/doi.org\/10.1111\/hiv.70025.","journal-title":"HIV Med"},{"issue":"9","key":"1430_CR22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1056\/NEJMoa2508228","volume":"394","author":"AI Rana","year":"2026","unstructured":"Rana AI, Zheng L, Castillo-Mancilla J, Bao Y, Sieczkarski S, Brooks KM, et al. Cabotegravir plus rilpivirine for persons with HIV and adherence challenges. N Engl J Med. 2026;394(9):858\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2508228.","journal-title":"N Engl J Med"},{"issue":"1","key":"1430_CR23","doi-asserted-by":"publisher","first-page":"ofaf817","DOI":"10.1093\/ofid\/ofaf817","volume":"13","author":"A Calcagno","year":"2026","unstructured":"Calcagno A, Candela C, Riva A, Calza S, Fioretti B, Gardini S, et al. Bimonthly administered long-acting cabotegravir and rilpivirine are highly effective and well-tolerated in people with human immunodeficiency virus above 65 years. Open Forum Infect Dis. 2026;13(1):ofaf817. https:\/\/doi.org\/10.1093\/ofid\/ofaf817.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"1430_CR24","doi-asserted-by":"publisher","first-page":"ofae326","DOI":"10.1093\/ofid\/ofae326","volume":"11","author":"C Muccini","year":"2024","unstructured":"Muccini C, Gianotti N, Diotallevi S, Lolatto R, Spagnuolo V, Canetti D, et al. One year of long-acting cabotegravir and rilpivirine in people with human immunodeficiency virus and long exposure to antiretroviral therapy: data from the SCohoLART study. Open Forum Infect Dis. 2024;11(7):ofae326. https:\/\/doi.org\/10.1093\/ofid\/ofae326.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1430_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/hiv.70119","volume":"27","author":"G Schuettfort","year":"2026","unstructured":"Schuettfort G, Borch J, Cabello A, Crusells M, G\u00f3rgolas M, Herrmann E, et al. Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG\/3TC or BIC\/TAF\/FTC: a real-world cohort analysis. HIV Med. 2026;27(1):96\u2013105. https:\/\/doi.org\/10.1111\/hiv.70119.","journal-title":"HIV Med"},{"issue":"1","key":"1430_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/QAI.0000000000003600","volume":"99","author":"L Calza","year":"2025","unstructured":"Calza L, Colangeli V, Giglia M, Rigamonti C, Bon I, Cretella S, et al. Efficacy and safety of dolutegravir\/lamivudine in antiretroviral therapy-naive people living with HIV-1 and with high-level viremia. J Acquir Immune Defic Syndr. 2025;99(1):93\u20137. https:\/\/doi.org\/10.1097\/QAI.0000000000003600.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"1430_CR27","doi-asserted-by":"publisher","first-page":"ofad101","DOI":"10.1093\/ofid\/ofad101","volume":"10","author":"CP Rolle","year":"2023","unstructured":"Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, et al. Sustained virologic suppression with dolutegravir\/lamivudine in a test-and-treat setting through 48 weeks. Open Forum Infect Dis. 2023;10(3):ofad101. https:\/\/doi.org\/10.1093\/ofid\/ofad101.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"1430_CR28","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2352-3018(24)00294-7","volume":"12","author":"E Cordova","year":"2025","unstructured":"Cordova E, Hernandez Rendon J, Mingrone V, Martin P, Arevalo Calderon G, Seleme S, et al. Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial. Lancet HIV. 2025;12(2):e95-104. https:\/\/doi.org\/10.1016\/S2352-3018(24)00294-7.","journal-title":"Lancet HIV"},{"issue":"11","key":"1430_CR29","doi-asserted-by":"publisher","first-page":"ofad526","DOI":"10.1093\/ofid\/ofad526","volume":"10","author":"M Kabra","year":"2023","unstructured":"Kabra M, Barber TJ, Allavena C, Marcelin AG, Di Giambenedetto S, Pasquau J, et al. Virologic response to dolutegravir plus lamivudine in people with suppressed human immunodeficiency virus type 1 and historical M184V\/I: A systematic literature review and meta-analysis. Open Forum Infect Dis. 2023;10(11):ofad526. https:\/\/doi.org\/10.1093\/ofid\/ofad526.","journal-title":"Open Forum Infect Dis"},{"key":"1430_CR30","unstructured":"Orkin C, Short W R, Kolobova I, Danchenko N, Augusto I, Brown K, et al. Real-world effectiveness and tolerability of cabotegravir + rilpivirine long-acting in people living with HIV-1: a meta-analysis of real-world evidence. In: Poster P103. Paris; 2025."},{"issue":"4","key":"1430_CR31","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/QAD.0000000000004388","volume":"40","author":"L Buz\u00f3n-Mart\u00edn","year":"2026","unstructured":"Buz\u00f3n-Mart\u00edn L, Bernardino JI, Galindo Puerto MJ, Mart\u00edn-Torres J, Alem\u00e1n Valls MR, Torralba Gonz\u00e1lez de Suso M, et al. Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort. AIDS. 2026;40(4):414\u201327. https:\/\/doi.org\/10.1097\/QAD.0000000000004388.","journal-title":"AIDS"},{"issue":"12","key":"1430_CR32","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1093\/jac\/dkaf389","volume":"80","author":"L Buz\u00f3n-Mart\u00edn","year":"2025","unstructured":"Buz\u00f3n-Mart\u00edn L, Montes ML, Pedrero R, Galindo MJ, Santacreu-Guerrero M, Alem\u00e1n MR, et al. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study). J Antimicrob Chemother. 2025;80(12):3438\u201351. https:\/\/doi.org\/10.1093\/jac\/dkaf389.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1430_CR33","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/jac\/dkaf025","volume":"80","author":"L Taramasso","year":"2025","unstructured":"Taramasso L, Bonora S, Cingolani A, Di Biagio A, Gianotti N, Guaraldi G, et al. Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV. J Antimicrob Chemother. 2025;80(3):610\u201323. https:\/\/doi.org\/10.1093\/jac\/dkaf025.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1430_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/QAD.0000000000004040","volume":"39","author":"J Alagaratnam","year":"2025","unstructured":"Alagaratnam J, Kelly N, Dustan S, Naous N, Nwanbila M, Byrne R, et al. Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir\/rilpivirine. AIDS. 2025;39(1):95\u20138. https:\/\/doi.org\/10.1097\/QAD.0000000000004040.","journal-title":"AIDS"},{"issue":"4","key":"1430_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1089\/apc.2025.0010","volume":"39","author":"G Cologgi","year":"2025","unstructured":"Cologgi G, Bartalucci C, Melchio M, Taramasso L, Bruzzone B, Bassetti M, et al. A proposal for a tool to reduce the frequency of HIV RNA monitoring in people with HIV treated with long-acting antiretrovirals. AIDS Patient Care STDS. 2025;39(4):125\u20138. https:\/\/doi.org\/10.1089\/apc.2025.0010.","journal-title":"AIDS Patient Care STDS"},{"key":"1430_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106898","volume":"196","author":"L Taramasso","year":"2023","unstructured":"Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, et al. Pillars of long-term antiretroviral therapy success. Pharmacol Res. 2023;196:106898. https:\/\/doi.org\/10.1016\/j.phrs.2023.106898.","journal-title":"Pharmacol Res"},{"issue":"338","key":"1430_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a3172","volume":"26","author":"SG Deeks","year":"2009","unstructured":"Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;26(338):a3172. https:\/\/doi.org\/10.1136\/bmj.a3172.","journal-title":"BMJ"},{"issue":"12","key":"1430_CR38","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787\u201397. https:\/\/doi.org\/10.1093\/cid\/ciu701.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1430_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","volume":"36","author":"P Cahn","year":"2022","unstructured":"Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy\u2014naive adults with HIV-1 infection. AIDS. 2022;36(1):39\u201348. https:\/\/doi.org\/10.1097\/QAD.0000000000003070.","journal-title":"AIDS"},{"issue":"9","key":"1430_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1089\/apc.2021.0089","volume":"35","author":"L Taramasso","year":"2021","unstructured":"Taramasso L, De Vito A, Ricci ED, Orofino G, Squillace N, Menzaghi B, et al. Durability of dolutegravir-based regimens: a 5-year prospective observational study. AIDS Patient Care STDS. 2021;35(9):342\u201353. https:\/\/doi.org\/10.1089\/apc.2021.0089.","journal-title":"AIDS Patient Care STDS"},{"issue":"2","key":"1430_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40121-024-01103-0","volume":"14","author":"J Fraysse","year":"2025","unstructured":"Fraysse J, Priest J, Turner M, Hill S, Jones B, Verdier G, et al. Real-world effectiveness and tolerability of dolutegravir and lamivudine 2-drug regimen in people living with HIV: systematic literature review and meta-analysis. Infect Dis Ther. 2025;14(2):357\u201383. https:\/\/doi.org\/10.1007\/s40121-024-01103-0.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"1430_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/QAI.0000000000002655","volume":"87","author":"J van Wyk","year":"2021","unstructured":"van Wyk J, Ait-Khaled M, Santos J, Scholten S, Wohlfeiler M, Ajana F, et al. Brief report: improvement in metabolic health parameters at week 48 after switching from a tenofovir alafenamide-based 3- or 4-drug regimen to the 2-drug regimen of dolutegravir\/lamivudine: the TANGO study. J Acquir Immune Defic Syndr. 2021;87(2):794\u2013800. https:\/\/doi.org\/10.1097\/QAI.0000000000002655.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1430_CR43","doi-asserted-by":"crossref","unstructured":"Baldin M, Ciccullo A, Cervo A, Oreni L, Mazzitelli M, Lagi F, et al. Ten-year results on the effectiveness of DTG+3TC as a switch regimen in the ODOACRE cohort. [cited 2026 Apr 10]. https:\/\/eacs2025.abstractserver.com\/program\/#\/details\/presentations\/879.","DOI":"10.1136\/sextrans-ICAR-2025.48"},{"issue":"1","key":"1430_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12879-023-08174-3","volume":"23","author":"G Guaraldi","year":"2023","unstructured":"Guaraldi G, Bonfanti P, Di Biagio A, Gori A, Mili\u0107 J, Saltini P, et al. Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda. BMC Infect Dis. 2023;23(1):230. https:\/\/doi.org\/10.1186\/s12879-023-08174-3.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"1430_CR45","doi-asserted-by":"publisher","first-page":"ofaa195","DOI":"10.1093\/ofid\/ofaa195","volume":"7","author":"L Taramasso","year":"2020","unstructured":"Taramasso L, Bonfanti P, Ricci E, Orofino G, Squillace N, Menzaghi B, et al. Factors associated with weight gain in people treated with dolutegravir. Open Forum Infect Dis. 2020;7(6):ofaa195. https:\/\/doi.org\/10.1093\/ofid\/ofaa195.","journal-title":"Open Forum Infect Dis"},{"key":"1430_CR46","unstructured":"Masia M, Domingo P, Curran A, Guerri-Fernandez R, Bernal E, Bravo J, et al. Virological non-inferiority and lower weight gain with DTG\/3TC versus BIC\/FTC\/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, open-label, non-inferiority trial. In: Abstract RO3.8.LB. Paris. https:\/\/www.abstractserver.com\/eacsabstractarchive\/."},{"issue":"2","key":"1430_CR47","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1093\/cid\/ciaf565","volume":"82","author":"S Serrano-Villar","year":"2026","unstructured":"Serrano-Villar S, Mart\u00edn-Pedraza L, Tiraboschi J, Novella M, Cabello-\u00dabeda A, L\u00f3pez-Cort\u00e9s L, et al. Comparable inflammatory and metabolic outcomes after switching to bictegravir\/emtricitabine\/tenofovir alafenamide versus continuing dolutegravir\/lamivudine in virologically suppressed adults with HIV (INSTINCT\/GESIDA10918 study). Clin Infect Dis. 2026;82(2):e262\u201374. https:\/\/doi.org\/10.1093\/cid\/ciaf565.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1430_CR48","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3390\/v17081108","volume":"17","author":"M Bottanelli","year":"2025","unstructured":"Bottanelli M, Castagna A, Muccini C. Safety, tolerability, and metabolic effects of long-acting cabotegravir and rilpivirine in HIV care: a comprehensive review. Viruses. 2025;17(8):1108. https:\/\/doi.org\/10.3390\/v17081108.","journal-title":"Viruses"},{"issue":"6","key":"1430_CR49","doi-asserted-by":"publisher","first-page":"ofae282","DOI":"10.1093\/ofid\/ofae282","volume":"11","author":"P Teichner","year":"2024","unstructured":"Teichner P, Chamay N, Elliot E, Pascual-Bern\u00e1ldez M, Merrill D, Garris C, et al. Cabotegravir + rilpivirine long-acting: overview of injection guidance, injection site reactions, and best practices for intramuscular injection administration. Open Forum Infect Dis. 2024;11(6):ofae282. https:\/\/doi.org\/10.1093\/ofid\/ofae282.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"1430_CR50","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1007\/s12325-023-02656-1","volume":"40","author":"V Chounta","year":"2023","unstructured":"Chounta V, Byrnes HF, Henry-Szatkowski M, Browning D, Donatti C, Lambert J. Psychometric validation of the perception of injection (PIN) questionnaire using data from two phase III, open-label, active-controlled, non-inferiority studies in people living with HIV. Adv Ther. 2023;40(12):5300\u201314. https:\/\/doi.org\/10.1007\/s12325-023-02656-1.","journal-title":"Adv Ther"},{"issue":"1","key":"1430_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/v18010007","volume":"18","author":"M Mazzitelli","year":"2025","unstructured":"Mazzitelli M, Bargiacchi O, Carleo MA, Giacomelli A, Muccini C, Taramasso L, et al. PROs assessment in dual (either oral or injectable) antiretroviral regimen in people with HIV: a narrative review. Viruses. 2025;18(1):7. https:\/\/doi.org\/10.3390\/v18010007.","journal-title":"Viruses"},{"issue":"8","key":"1430_CR52","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/jac\/dkaf184","volume":"80","author":"R Gagliardini","year":"2025","unstructured":"Gagliardini R, De Benedittis S, Tavelli A, Lapadula G, Mazzotta V, Bruzzesi E, et al. Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir\/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort. J Antimicrob Chemother. 2025;80(8):2169\u201378. https:\/\/doi.org\/10.1093\/jac\/dkaf184.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1430_CR53","doi-asserted-by":"publisher","first-page":"ofae26","DOI":"10.1093\/ofid\/ofae326","volume":"11","author":"C Muccini","year":"2024","unstructured":"Muccini C, Gianotti N, Diotallevi S, Lolatto R, Spagnuolo V, Canetti D, et al. One year of long-acting cabotegravir and rilpivirine in people with human immunodeficiency virus and long exposure to antiretroviral therapy: data from the SCohoLART study. Open Forum Infect Dis. 2024;11(7):ofae26. https:\/\/doi.org\/10.1093\/ofid\/ofae326.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"1430_CR54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/QAI.0000000000003584","volume":"98","author":"DHS Tan","year":"2025","unstructured":"Tan DHS, Antinori A, Eu B, Galindo Puerto MJ, Kinder C, Sweet D, et al. Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir\/emtricitabine\/tenofovir alafenamide. J Acquir Immune Defic Syndr. 2025;98(4):401\u20139. https:\/\/doi.org\/10.1097\/QAI.0000000000003584.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"1430_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107312","volume":"64","author":"C Muccini","year":"2024","unstructured":"Muccini C, Diotallevi S, Lolatto R, Piromalli G, Spagnuolo V, Castagna A. Improvement in high-density lipoprotein cholesterol in people with HIV who switched from a tenofovir alafenamide-containing regimen to cabotegravir plus rilpivirine. Int J Antimicrob Agents. 2024;64(4):107312. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107312.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"1430_CR56","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1097\/QAI.0000000000003719","volume":"100","author":"M Ranzenigo","year":"2025","unstructured":"Ranzenigo M, Diotallevi S, Lolatto R, Castagna A, Muccini C. Prevalence and incidence of metabolic syndrome in people with HIV receiving cabotegravir and rilpivirine. J Acquir Immune Defic Syndr. 2025;100(2):e2-3. https:\/\/doi.org\/10.1097\/QAI.0000000000003719.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1430_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-023-00590-4","volume":"21","author":"E Adachi","year":"2024","unstructured":"Adachi E, Saito M, Otani A, Koga M, Yotsuyanagi H. Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine. AIDS Res Ther. 2024;21(1):1. https:\/\/doi.org\/10.1186\/s12981-023-00590-4.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"1430_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/microorganisms14010022","volume":"14","author":"MS D\u00edaz","year":"2025","unstructured":"D\u00edaz MS, Romacho AC, Murcia SF. Impact of switching from oral to long-acting injectable cabotegravir and rilpivirine on the lipid profile of HIV-positive patients. Microorganisms. 2025;14(1):22. https:\/\/doi.org\/10.3390\/microorganisms14010022.","journal-title":"Microorganisms"},{"key":"1430_CR59","unstructured":"National Institute of Health (NIH). HIV treatment. [cited 2026 Mar 23]. https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/hiv-treatment-adherence."},{"issue":"10","key":"1430_CR60","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1177\/09564624231169329","volume":"34","author":"KKV Mate","year":"2023","unstructured":"Mate KKV, Engler K, Lessard D, Lebouch\u00e9 B. Barriers to adherence to antiretroviral therapy: identifying priority areas for people with HIV and healthcare professionals. Int J STD AIDS. 2023;34(10):677\u201386. https:\/\/doi.org\/10.1177\/09564624231169329.","journal-title":"Int J STD AIDS"},{"issue":"3","key":"1430_CR61","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/psp4.4","volume":"4","author":"P Assawasuwannakit","year":"2015","unstructured":"Assawasuwannakit P, Braund R, Duffull S. Quantification of the forgiveness of drugs to imperfect adherence. CPT Pharmacometrics Syst Pharmacol. 2015;4(3):204\u201311. https:\/\/doi.org\/10.1002\/psp4.4.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1430_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2024-056202","author":"F Maggiolo","year":"2024","unstructured":"Maggiolo F, Taramasso L, Valenti D, Blanchi S, Centorrino F, Comi L, et al. B\/F\/TAF forgiveness to non-adherence. Sex Transm Infect. 2024. https:\/\/doi.org\/10.1136\/sextrans-2024-056202.","journal-title":"Sex Transm Infect."},{"issue":"5","key":"1430_CR63","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/QAI.0000000000003594","volume":"98","author":"L Taramasso","year":"2025","unstructured":"Taramasso L, Maggiolo F, Valenti D, Blanchi S, Centorrino F, Comi L, et al. Adherence and forgiveness of two modern ART regimens: lamivudine\/dolutegravir and emtricitabine\/tenofovir alafenamide\/rilpivirine. J Acquir Immune Defic Syndr. 2025;98(5):484\u201390. https:\/\/doi.org\/10.1097\/QAI.0000000000003594.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1430_CR64","doi-asserted-by":"publisher","first-page":"ofad230","DOI":"10.1093\/ofid\/ofad230","volume":"10","author":"JR Castillo-Mancilla","year":"2023","unstructured":"Castillo-Mancilla JR, Morrow M, Hunt PW, Schnittman SR, Phillips AN, Baker JV, et al. Beyond undetectable: modeling the clinical benefit of improved antiretroviral adherence in persons with human immunodeficiency virus with virologic suppression. Open Forum Infect Dis. 2023;10(5):ofad230. https:\/\/doi.org\/10.1093\/ofid\/ofad230.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1430_CR65","doi-asserted-by":"publisher","first-page":"ofax275","DOI":"10.1093\/ofid\/ofx275","volume":"5","author":"JR Castillo-Mancilla","year":"2018","unstructured":"Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Collins S, Mannheimer S, et al. Association of suboptimal antiretroviral therapy adherence with inflammation in virologically suppressed individuals enrolled in the SMART study. Open Forum Infect Dis. 2018;5(1):ofax275. https:\/\/doi.org\/10.1093\/ofid\/ofx275.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"1430_CR66","doi-asserted-by":"publisher","first-page":"e587","DOI":"10.1016\/S2352-3018(25)00096-7","volume":"12","author":"CM Keene","year":"2025","unstructured":"Keene CM, Sabin LL, Jennings L, Schreuder C, K\u00e4llstr\u00f6m-St\u00e5hlgren CO, Katz IT, et al. Oral antiretroviral adherence interventions in the era of U=U. Lancet HIV. 2025;12(8):e587\u201395. https:\/\/doi.org\/10.1016\/S2352-3018(25)00096-7.","journal-title":"Lancet HIV"},{"key":"1430_CR67","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390. https:\/\/doi.org\/10.2147\/PPA.S192735.","journal-title":"Patient Prefer Adherence"},{"key":"1430_CR68","unstructured":"Garris C, Desai R, Chang R, Chen Z, Liu D, DerSarkissian M, et al. ABOVE study: higher real-world adherence and persistence with CAB + RPV LA compared to oral ART among PWH in the US. In: JMCP supplement. Poster abstracts. Las Vegas, 2024; [cited 2026 Mar 25]. https:\/\/amcpnexus.org\/sites\/default\/files\/2024-10\/2024%20October%20JMCP%20Poster%20Abstract%20Supplement-1.pdf."},{"issue":"4","key":"1430_CR69","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/cid\/ciae500","volume":"80","author":"MD Hickey","year":"2025","unstructured":"Hickey MD, Gistand N, Grochowski J, Mayorga-Munoz F, Imbert E, Szumowski JD, et al. Viral suppression rates at 48 weeks in people with HIV starting long-acting cabotegravir\/rilpivirine with initial viremia. Clin Infect Dis. 2025;80(4):864\u201370. https:\/\/doi.org\/10.1093\/cid\/ciae500.","journal-title":"Clin Infect Dis"},{"key":"1430_CR70","unstructured":"Gaur A, Baltrusaitis K, Capparelli E V, Lowenthal E, Marzinke M, Crauwels H. Next-generation HIV strategies for children and adolescents: breakthroughs in pediatric HIV prevention, treatment, and care. In: Abstract Number 155. Denver, CO; 2026. https:\/\/www.croiconference.org\/abstract\/453-2026\/."},{"issue":"4","key":"1430_CR71","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(23)00300-4","volume":"11","author":"AH Gaur","year":"2024","unstructured":"Gaur AH, Capparelli EV, Calabrese K, Baltrusaitis K, Marzinke MA, McCoig C, et al. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017\/MOCHA): a phase 1\/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2024;11(4):e211\u201321. https:\/\/doi.org\/10.1016\/S2352-3018(23)00300-4.","journal-title":"Lancet HIV"},{"issue":"5","key":"1430_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2026.103207","volume":"19","author":"B Lazaro-Martin","year":"2026","unstructured":"Lazaro-Martin B, Tarancon-Diez L, Burgos J, \u00c1lvarez Vallejo B, Ibarra S, Garrote E, et al. Use of long-acting therapies for the HIV treatment in the Spanish pediatric cohort (CoRISpe). J Infect Public Health. 2026;19(5):103207. https:\/\/doi.org\/10.1016\/j.jiph.2026.103207.","journal-title":"J Infect Public Health"},{"issue":"7","key":"1430_CR73","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/INF.0000000000004742","volume":"44","author":"T Williams","year":"2025","unstructured":"Williams T, Unternaher J, Koay WLA, Anderson L, Bright K, Mareuil J, et al. Efficacy, safety and retention in care among adolescents and youth with HIV on long-acting injectable cabotegravir\/rilpivirine treatment: real-world observational cohort outcomes. Pediatr Infect Dis J. 2025;44(7):650\u20136. https:\/\/doi.org\/10.1097\/INF.0000000000004742.","journal-title":"Pediatr Infect Dis J"},{"key":"1430_CR74","unstructured":"Cresswell F V, Kafeero P, Norcross C, Tumusiime V, Achieng Ombajo L, Garrett N. Long\u2010acting cabotegravir and rilpivirine in adults with suboptimal HIV control in sub\u2010Saharan Africa: the IMPALA trial 48\u2010week results. In: Abstract OAS0105LB. Kigali, Rwanda; 2025. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12257635\/."},{"key":"1430_CR75","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, A Working Group of the Office of AIDS Research, Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf."},{"key":"1430_CR76","unstructured":"European AIDS Clinical Society (EACS). EACS guidelines 2025. Version 13.0. https:\/\/eacs.sanfordguide.com."},{"issue":"2","key":"1430_CR77","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40271-025-00779-x","volume":"19","author":"J Slim","year":"2026","unstructured":"Slim J, Brogan AP, Harper G, Mycock K, McMillan A, Merrill D, et al. PAIRED: Quantitative and Qualitative PAtIent-Reported Experiences and perceiveD Benefit of treatment with dolutegravir\/lamivudine in the United States. Patient. 2026;19(2):231\u201344. https:\/\/doi.org\/10.1007\/s40271-025-00779-x.","journal-title":"Patient"},{"issue":"1","key":"1430_CR78","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10461-024-04479-9","volume":"29","author":"P Kumar","year":"2025","unstructured":"Kumar P, Clarke AE, Jonsson-Oldenb\u00fcttel C, Deltoro MG, Di Giambenedetto S, Brites C, et al. Patient-reported outcomes after switching to a 2-drug regimen of fixed-dose combination dolutegravir\/lamivudine: 48-week results from the SALSA study. AIDS Behav. 2025;29(1):235\u201345. https:\/\/doi.org\/10.1007\/s10461-024-04479-9.","journal-title":"AIDS Behav"},{"key":"1430_CR79","doi-asserted-by":"publisher","first-page":"204993612513217","DOI":"10.1177\/20499361251321728","volume":"12","author":"M Duracinsky","year":"2025","unstructured":"Duracinsky M, Alain T, Zucman D, Rousset Torrente O, Brown Hajdukova E, Hocqueloux L, et al. Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir\/lamivudine: results from the PROBI study. Ther Adv Infect Dis. 2025;12:20499361251321730. https:\/\/doi.org\/10.1177\/20499361251321728.","journal-title":"Ther Adv Infect Dis"},{"issue":"5","key":"1430_CR80","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/ofid\/ofaf220","volume":"12","author":"D Dandachi","year":"2025","unstructured":"Dandachi D, Garris C, Richardson D, Sinclair G, Cunningham D, Valenti W, et al. Clinical outcomes and perspectives of people with human immunodeficiency virus type 1 twelve months after initiation of long-acting cabotegravir and rilpivirine in an observational real-world US study (BEYOND). Open Forum Infect Dis. 2025;12(5):220. https:\/\/doi.org\/10.1093\/ofid\/ofaf220.","journal-title":"Open Forum Infect Dis"},{"key":"1430_CR81","unstructured":"World Health Organization (WHO). Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030, 2022. [cited 2026 Mar 12]. https:\/\/www.who.int\/publications\/i\/item\/9789240053779."},{"issue":"1","key":"1430_CR82","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S2352-3018(19)30345-5","volume":"7","author":"M Kall","year":"2020","unstructured":"Kall M, Marcellin F, Harding R, Lazarus JV, Carrieri P. Patient-reported outcomes to enhance person-centred HIV care. Lancet HIV. 2020;7(1):e59-68. https:\/\/doi.org\/10.1016\/S2352-3018(19)30345-5.","journal-title":"Lancet HIV"},{"issue":"9","key":"1430_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26006","volume":"25","author":"CP Garris","year":"2022","unstructured":"Garris CP, Czarnogorski M, Dalessandro M, D\u2019Amico R, Nwafor T, Williams W, et al. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study. J Int AIDS Soc. 2022;25(9):e26006. https:\/\/doi.org\/10.1002\/jia2.26006.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"1430_CR84","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masi\u00e1 M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1904398.","journal-title":"N Engl J Med"},{"issue":"11","key":"1430_CR85","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","volume":"8","author":"C Orkin","year":"2021","unstructured":"Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021;8(11):e668\u201378. https:\/\/doi.org\/10.1016\/S2352-3018(21)00184-3.","journal-title":"Lancet HIV"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01430-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:13:12Z","timestamp":1791864792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01430-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":85,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1430"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01430-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lucia Taramasso attended Advisory boards sponsored by ViiV Healthcare, Gilead Sciences and MSD and received support for participation to international conferences from ViiV Healthcare and Gilead Sciences. Camilla Muccini received speaking fees by Gilead Sciences, ViiV Healthcare and Janssen-Cilag. Stefano Rusconi reports personal fees for advisory boards, speaker panels and educational materials from Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme, Glaxo Smith Kline and AstraZeneca, and research grants from Gilead Sciences and ViiV Healthcare. Roberto Rossotti received personal fees for advisory board and speaker panel participation from Gilead Sciences, ViiV Healthcare, MSD and Johnson & Johnson, and research grants from Gilead Sciences. Roberta Gagliardini received personal fees for advisory board and speaker panel participation from Gilead Sciences and ViiV Healthcare. The research contribution of RG was partially granted by the Ricerca Corrente Linea 2-progetto 2 of the Ministry of Health, Italy (National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS). Giovanni Guaraldi Received research grant and speaker honorarium from Gilead, ViiV, MERCK and Jansen and attended advisory boards of Gilead, ViiV and MERCK. Diego Ripamonti received speakers\u2019 honoraria from Gilead Sciences and ViiV Healthcare and MSD and he has been an advisor for Gilead Sciences, and MSD, DR received travel reimbursement by Giled and Viiv healthcare. Simona Di Giambenedetto received speakers\u2019 honoraria from Gilead Sciences and ViiV Healthcare, has been an advisor for ViiV Healthcare, Gilead Sciences and MSD, travel reimbursement by Gilead Sciences, and has received grant for research from Gilead Sciences and ViiV healthcare. Antonio Di Biagio received speakers\u2019 honoraria from Gilead Sciences and ViiV Healthcare, has been an advisor for ViiV Healthcare, Gilead Sciences and MSD, travel reimbursement by Gilead Sciences, and has received grant for research from Gilead Sciences and ViiV healthcare. Vincenzo Esposito reports personal fees for advisory boards, speaker panels and educational materials from Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme, Glaxo Smith Kline, AstraZeneca and Zambon, and research grants from Gilead Sciences and ViiV Healthcare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}